Gainers

• Milestone Scientific (AMEX:MLSS) stock moved upwards by 19.5% to $0.36 during Friday's pre-market session. The company's market cap stands at $27.1 million.
• Eton Pharmaceuticals (NASDAQ:ETON) shares rose 18.89% to $56.06. The company's market cap stands at $1.3 billion. The company's, Q3 earnings came out yesterday.
• Advanced Biomed (NASDAQ:ADVB) shares rose 18.42% to $2.25. The company's market cap stands at $3.1 million.
• Kyverna Therapeutics (NASDAQ:KYTX) stock moved upwards by 14.31% to $5.27. The market value of their outstanding shares is at $285.0 million.
• Nano X Imaging (NASDAQ:NNOX) stock increased by 11.96% to $0.28. The company's market cap stands at $19.5 million.
• Liminatus Pharma (NASDAQ:LIMN) shares rose 11.78% to $2.94. The market value of their outstanding shares is at $3.5 million.

Losers

• Biodesix (NASDAQ:BDSX) stock declined by 37.3% to $12.44 during Friday's pre-market session. The company's market cap stands at $205.4 million. The company's, Q3 earnings came out yesterday.
• Baird Medical Investment (NASDAQ:BDMD) stock declined by 32.7% to $0.11. The company's market cap stands at $5.0 million.
• Inovio Pharmaceuticals (NASDAQ:INO) shares declined by 19.31% to $1.17. The market value of their outstanding shares is at $149.9 million.
• NewcelX (NASDAQ:NCEL) stock declined by 19.04% to $2.34. The company's market cap stands at $16.6 million.
• YD Bio (NASDAQ:YDES) shares fell 18.11% to $5.88. The market value of their outstanding shares is at $508.5 million.
• Starling Oncology (NASDAQ:STLN) stock decreased by 17.92% to $5.5. The market value of their outstanding shares is at $669.8 million. As per the news, the Q3 earnings report came out yesterday. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.